SOURCE: Implant Sciences

Implant Sciences

September 20, 2011 07:00 ET

Implant Sciences Granted U.S. Patent for Explosives Trace Detection Technology

WILMINGTON, MA--(Marketwire - Sep 20, 2011) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that it has been issued patent #7,994,453 from the United Stated Patent and Trademark Office. The patent, titled "Flash Heating for Tubing," describes a method for cleaning the sample tube of a chemical detection system. Keeping the sample tube clean is important for obtaining accurate analysis results.

Todd Silvestri, Implant Sciences' Vice President of Technology, commented, "Our vision is to use our intellectual property to improve security and make it easier for security professionals to do their jobs. This innovation will result in faster sampling throughput, improving overall system efficiency."

Glenn D. Bolduc, President and CEO, added, "The innovations of our engineering team lead directly to the increasing acceptance of our products in the field. Our growing patent portfolio, which includes non-radioactive ion generation, the technology behind our fully automatic self-calibration system, and non-contact sampling, fortifies our competitive position and supports shareholder value."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism Technology and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact